Pilot Trial of Supplemental Vitamin A and Nicotinamide
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorRhode Island Hospital
About this trial
The goal of this clinical trial is to assess the feasibility and safety of oral nicotinamide (NAM; a derivative of vitamin B3 \[niacin\]) and vitamin A in a high-risk population of kidney transplant recipients with a history of skin cancer to generate preliminary data for future cancer prevention clinical trials.
Eligibility criteria
Qualifiers
18 years old or greater;
Either History of 2 or more histologically confirmed invasive cutaneous SCCs in the past 2 years or
At least one previously billed Healthcare Common Procedure Coding System code 17004 (destruction of 15 or more benign or premalignant lesions of the integumentary system);
Understands, reads, and writes English proficiently.
Disqualifiers
Liver disease;
Active peptic ulcer disease;
Recent myocardial infarction;
Hypotension;
Trial design
Treatments tested in this trial
- Vitamin A
- Nicotinamide
- Other: Placebo
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov